{
  "outcomes_metadata": {
    "timestamp": "2025-10-04T14:25:27.948196",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 126,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "perioperative mortality",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "death (partitioned survival model)",
        "survival",
        "improved survival",
        "mortality",
        "treatment-related deaths",
        "treatment-related mortality",
        "recipient deaths"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "objective response rate (ORR)",
        "tumor response rate",
        "tumour response rate",
        "response (mRECIST)",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "response rates (multiphase computed tomography with contrast)",
        "response rates (magnetic resonance imaging with contrast)",
        "partial response (PR)",
        "partial response",
        "minor response (reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "complete remission",
        "objective tumour response",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "clinical benefit rate (CBR)",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "local control",
        "tumor reduction",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "progression-free state (partitioned survival model)",
        "progressive illness state (partitioned survival model)",
        "tumour spread (TNM system)",
        "effectiveness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "bridging therapy (reduction of progression)",
        "resectability",
        "down-staging"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time-to-progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to deterioration",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "disease progression",
        "disease recurrence",
        "recurrence",
        "delay of recurrence",
        "tumour seeding",
        "tumour haemorrhage",
        "secondary cancer",
        "tumour spread (TNM system)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse reactions (general)",
        "adverse reactions leading to discontinuation of treatment",
        "adverse events leading to discontinuation",
        "treatment-emergent adverse events (TEAE)",
        "treatment-emergent adverse events (TEAEs)",
        "grade 3 adverse events",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "serious adverse events",
        "serious complications",
        "complications",
        "complication incidence",
        "post-treatment complications",
        "long-term treatment-related complications",
        "intraoperative complications",
        "morbidity",
        "neurotoxicity",
        "toxicity",
        "side-effects (biopsy)",
        "undesirable effects",
        "bleeding",
        "haemorrhagic events",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "haemorrhage",
        "tumour haemorrhage",
        "gastrointestinal disorders",
        "liver disorders",
        "liver failure",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "hepatic encephalopathy (grade > 1 on the New Haven criteria)",
        "portal vein thrombosis",
        "portal hypertension",
        "ascites",
        "renal events",
        "renal failure",
        "proteinuria",
        "hypertension",
        "arterial hypertension",
        "arterial thromboembolic events",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "cardiovascular arrest",
        "cerebral vascular accident",
        "sudden death",
        "death",
        "infusion reactions",
        "infections",
        "sepsis",
        "lymphopenia",
        "neutropenia",
        "leukopenia",
        "anaemia",
        "thrombocytopenia",
        "hypothyroidism",
        "hyperthyroidism",
        "diabetes mellitus",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "weight loss",
        "decreased weight",
        "decreased appetite",
        "anorexia",
        "fatigue",
        "asthenia",
        "pain",
        "abdominal pain",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "headache",
        "cough",
        "dyspnoea",
        "shortness of breath",
        "pleural effusion",
        "nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "dry skin",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "dermatitis exfoliative",
        "acne",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "alopecia",
        "folliculitis",
        "pruritus",
        "erythema",
        "flushing",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "hand feeding reactions",
        "dysphonia",
        "tinnitus",
        "visual analogue scale (as AE)",
        "depression",
        "peripheral sensory neuropathy",
        "dysgeusia",
        "influenza like illness",
        "fever",
        "abdominal swelling",
        "jaundice",
        "nutrition",
        "body image",
        "transient increase in transaminases",
        "increased ALT activity",
        "increased amylase",
        "increased lipase",
        "creatinine increase",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "vital signs",
        "electrocardiography",
        "QTc prolongation",
        "dropout rate for toxicity",
        "treatment-related deaths",
        "treatment-related mortality",
        "number needed to harm (NNH)"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "severe adverse events"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "health status (EQ-5D visual analogue scale)",
        "FACT-G (Functional Assessment of Cancer Therapy â€“ General)",
        "FACT-G GP5",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "BPI-SF",
        "visual analogue scale",
        "health-related quality of life (HRQoL)",
        "overall quality of life (measured with a validated and reliable instrument)",
        "impairment of quality of life (EORTC QLQ-C30 full scale)",
        "impairment of quality of life (EORTC QLQ-C30 fitness sub-scale)",
        "impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "global health status (EORTC QLQ-C30)"
      ],
      "functional_status": [
        "overall condition (ECOG Performance Status)",
        "Child-Pugh scale",
        "Child-Pugh score",
        "MELD score",
        "Barcelona Clinic Liver Cancer (BCLC) staging system",
        "BCLC staging classification",
        "prognosis (BCLC staging system)",
        "prognosis"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "distress",
        "physical complaints",
        "psychosocial complaints",
        "emotional complaints",
        "cognitive complaints",
        "behavioural complaints",
        "social complaints",
        "spiritual complaints",
        "nutrition",
        "pain",
        "body image"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness analysis",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis",
        "economic outcomes (cost-effectiveness analysis)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "need for use of medical resources",
        "number needed to treat (NNT)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "pharmacokinetic parameters",
        "plasma pharmacokinetics parameters",
        "pharmacokinetic/pharmacodynamic relationship",
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "diagnosis (multiphasic CT and MRI, LI-RADS v2018)",
        "diagnosis (contrast-enhanced ultrasound)",
        "diagnosis (biopsy)",
        "diagnosis (immunohistochemistry markers)",
        "diagnosis (genetic tests for metabolic diseases)",
        "pathological subtypes",
        "molecular subtypes",
        "early diagnosis",
        "false positives",
        "ultrasound surveillance",
        "intention-to-treat analysis",
        "Milan criteria",
        "UCSF-expanded criteria",
        "donor morbidity",
        "rebleeding",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "local control",
        "bridging therapy (reduction of progression)"
      ],
      "biomarkers": [
        "alpha-fetoprotein"
      ]
    }
  }
}